Cilengitide
- Generic Name
- Cilengitide
- Drug Type
- Small Molecule
- Chemical Formula
- C27H40N8O7
- CAS Number
- 188968-51-6
- Unique Ingredient Identifier
- 4EDF46E4GI
- Background
Cilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.
Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2009-02-12
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 232
- Registration Number
- NCT00842712
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
- Conditions
- Glioblastoma
- Interventions
- Radiation: Radiotherapy
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2017-01-30
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 265
- Registration Number
- NCT00813943
- Locations
- 🇩🇪
Please Contact the Merck KGaA Communication Center Located in, Darmstadt, Germany
🇺🇸Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Conditions
- Squamous Cell Cancer
- Interventions
- First Posted Date
- 2008-06-25
- Last Posted Date
- 2014-04-30
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 184
- Registration Number
- NCT00705016
- Locations
- 🇨🇭
Research Site, Geneva, Switzerland
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 545
- Registration Number
- NCT00689221
- Locations
- 🇺🇸
Please Contact U.S. Medical Information Located in, Rockland, Massachusetts, United States
🇩🇪Please Contact the Merck KGaA Communication Center Located in, Darmstadt, Germany
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
- Conditions
- Recurrent Childhood Anaplastic AstrocytomaRecurrent Childhood Cerebellar AstrocytomaChildhood High-grade Cerebral AstrocytomaRecurrent Childhood Anaplastic OligoastrocytomaChildhood High-grade Cerebellar AstrocytomaRecurrent Childhood Anaplastic OligodendrogliomaRecurrent Childhood Cerebral AstrocytomaRecurrent Childhood Brain TumorRecurrent Childhood GlioblastomaRecurrent Childhood Visual Pathway and Hypothalamic Glioma
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00679354
- Locations
- 🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸Children's Hospital Medical Center of Akron, Akron, Ohio, United States
🇺🇸T C Thompson Children's Hospital, Chattanooga, Tennessee, United States
Cilengitide in Treating Patients With Prostate Cancer
- Conditions
- Recurrent Prostate CancerStage IIA Prostate CancerStage III Prostate CancerStage IIB Prostate CancerStage I Prostate Cancer
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-04-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT00121238
- Locations
- 🇺🇸
University of Michigan University Hospital, Ann Arbor, Michigan, United States
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
- Conditions
- Adult Giant Cell GlioblastomaAdult GlioblastomaAdult GliosarcomaRecurrent Adult Brain Tumor
- Interventions
- Procedure: therapeutic conventional surgeryOther: pharmacological studyOther: laboratory biomarker analysis
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00112866
- Locations
- 🇺🇸
North American Brain Tumor Consortium, Watertown, Massachusetts, United States
Cilengitide in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Recurrent Prostate CancerStage IV Prostate Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 106
- Registration Number
- NCT00103337
- Locations
- 🇺🇸
University of Michigan University Hospital, Ann Arbor, Michigan, United States
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
- Conditions
- Glioblastoma Multiforme
- Interventions
- First Posted Date
- 2004-10-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- EMD Serono
- Target Recruit Count
- 81
- Registration Number
- NCT00093964
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Baylor University Medical Center at Dallas, Dallas, Texas, United States
🇺🇸University of Vermont/Fletcher Allen Healthcare, Burlington, Vermont, United States
Cilengitide in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Basophilic LeukemiaAdult Acute Eosinophilic LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Interventions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT00089388
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.